CYP2D6: A key enzyme in morphine synthesis in animals

被引:0
|
作者
Zhu, Wei [1 ]
机构
[1] SUNY Coll Old Westbury, Neurosci Res Inst, Old Westbury, NY 11568 USA
来源
MEDICAL SCIENCE MONITOR | 2008年 / 14卷 / 11期
关键词
morphine; CYP2D6; nicotine; alcohol; mu3; opiate receptor;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Our laboratory and others have demonstrated that animals can make morphine, meaning its biosynthetic pathway has been conserved during evolution. Among the many enzymes involved in this process, CYP2D6 is of particular importance because of its role in multiple steps of morphine precursor metabolism, as well as its distribution in a variety of tissues, such as neuronal and immune. Additionally, its genetic variations support its role in this process. Elucidating its role in the critical metablic processes involved with many drugs, not just opiate alkaloids may provide a critical understanding of induced addiction, analgesia, immune-and vascular regulation. Its presence in invertebrate tissues underscores its singular significance in these processes as well, allowing one to hypothesize its role in actions of many substances of abuse.
引用
收藏
页码:SC15 / SC18
页数:4
相关论文
共 50 条
  • [1] CYP2D6 -: a key enzyme in the metabolism of antidepressants and neuroleptics
    Sjöqvist, F
    PHARMACOPSYCHIATRY, 2005, 38 (01) : 64 - 64
  • [2] CYP2D6 is the Major Metabolizing Enzyme of Metoclopramide
    Briggs, Errran D.
    Bolles, Amanda K.
    Livezey, Mara R.
    Furge, Laura Lowe
    FASEB JOURNAL, 2013, 27
  • [3] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
    Nahid, N.
    Kanumuri, S.
    Sharma, A.
    Wang, D.
    Johnson, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S74 - S75
  • [4] Common mutant alleles of CYP2D6 causing the defect of CYP2D6 enzyme activity in a Japanese population
    Ishiguro, A
    Kubota, T
    Sasaki, H
    Yamada, Y
    Iga, T
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (04) : 414 - U3
  • [5] Is CYP2D6 phenotype predictable from CYP2D6 genotype?
    Kiss, Adam Ferenc
    Toth, Katalin
    Juhasz, Cintia
    Temesvari, Manna
    Paulik, Jozsef
    Hirka, Gabor
    Monostory, Katalin
    MICROCHEMICAL JOURNAL, 2018, 136 : 209 - 214
  • [6] The impact of CYP2D6*41 on CYP2D6 enzyme activity using phenotyping methods in urine, plasma, and saliva
    Jin, Ye
    Zhang, Shuquan
    Hu, Pei
    Zheng, Xin
    Guan, Xiaoduo
    Chen, Rui
    Zhang, Shuyang
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [7] Purification, biochemical characterization and comparative enzyme kinetics of recombinant human CYP2D6 1 and CYP2D6 2 variants
    Yu, AM
    Haining, RL
    BIOLOGICAL REACTIVE INTERMEDIATES VI: CHEMICAL AND BIOLOGICAL MECHANISMS IN SUSCEPTIBILITY TO AND PREVENTION OF ENVIRONMENTAL DISEASES, 2001, 500 : 327 - 330
  • [8] The Impact of CYP2D6 Genetic Polymorphisms on Postoperative Morphine Consumption
    Candiotti, Keith A.
    Yang, Zongqi
    Rodriguez, Yiliam
    Crescimone, Andres
    Sanchez, Greys C.
    Takacs, Peter
    Medina, Carlos
    Zhang, Yanping
    Liu, Huanliang
    Gitlin, Melvin C.
    PAIN MEDICINE, 2009, 10 (05) : 799 - 805
  • [9] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
    Abduljalil, K.
    Frank, D.
    Gaedigk, A.
    Klaassen, T.
    Tomalik-Scharte, D.
    Jetter, A.
    Jaehde, U.
    Kirchheiner, J.
    Fuhr, U.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651
  • [10] Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6
    Livezey, Mara R.
    Briggs, Erran D.
    Bolles, Amanda K.
    Nagy, Leslie D.
    Fujiwara, Rina
    Furge, Laura Lowe
    XENOBIOTICA, 2014, 44 (04) : 309 - 319